Syphilis Screening

This test detects treponemal antibodies that the immune system produces in direct response to Treponema pallidum. Unlike non-treponemal tests such as the RPR, treponemal antibodies are highly specific to syphilis and rarely produce false positive results.

A key characteristic of treponemal tests is that they typically remain positive for life once seroconversion has occurred, even after successful treatment. This means the test indicates whether a person has ever had syphilis, but it cannot distinguish between current and past infection on its own.

Detecting syphilis is essential because the infection can progress through increasingly severe stages if left untreated, ultimately affecting the cardiovascular and nervous systems. Early-stage syphilis is readily treatable with antibiotics.

The treponemal screening test is often used as an initial diagnostic step. When positive, it is typically paired with a non-treponemal test such as the RPR to assess disease activity and guide treatment decisions.

Screening is recommended for sexually active individuals at risk, including those with new or multiple partners, men who have sex with men, and individuals living with HIV. Routine screening is also standard during pregnancy to prevent congenital syphilis.

Testing is also appropriate when symptoms suggestive of syphilis appear, such as painless genital sores, body rash, or unexplained neurological symptoms. If you have been treated for syphilis in the past, discuss with your healthcare provider which test is most appropriate for follow-up.